Sai-Hong Ignatius Ou

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  

Sai-Hong Ignatius Ou
Jan 28, 2025, 15:02 | Insight
5 articles suggested by Vivek Subbiah
Vivek Subbiah shared a few must-reads papers: 1. Artificial Intelligence–Guided Lung Ultrasound by Nonexperts |…
Jan 13, 2025, 15:46 | Science
Vivek Subbiah: Interesting commentary on Weight gain and ALK inhibitors by Cathleen June Park, et al.
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared…
Dec 19, 2024, 11:54 | Opinion
Lung Cancer Trial Highlights from 2024 By Yakup Ergün
Yakup Ergün, Medical Oncologist at Antalya City Hospital, posted on X: “What happened in Lung…
Dec 2, 2024, 20:05 | Insight
Xiuning Le: RTK fusion-mediated resistance to EGFR-TKI in EGFR-mutated NSCLC
Xiuning Le, Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, shared…
Nov 25, 2024, 17:53 | Insight
Safety of Lorlatinib in ALK positive NSCLC
Biagio Ricciuti, Thoracic Medical Oncologist at Dana-Farber and Harvard Medical School, shared a recent article…
Nov 24, 2024, 13:36 | Insight
Eric K. Singhi: Is it time to universally prescribe 1L lorlatinib for all?
Eric K. Singhi, Assistant Professor in the Department of General Oncology within the Division of…
Aug 5, 2024, 01:55 | Societies
Scientific Committees at the ESMO Congress 2024
The ESMO Congress is a globally influential oncology platform that brings together clinicians, researchers, patient…
Aug 1, 2024, 13:21 | Opinion
Stephen Liu: The seminal PROFILE 1001 trial of crizotinib in ALK and ROS1 NSCLC
Stephen Liu shared on X: "Watch for a special episode of the IASLC podcast, Lung Cancer…
All: 8 Posts: 1 - 100
Special Coverage